Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Lancet ; 387(10016): 395-402, 2016 Jan 23.
Article in English | MEDLINE | ID: mdl-26211826

ABSTRACT

Long perceived as a form of exotic self-expression in some social fringe groups, tattoos have left their maverick image behind and become mainstream, particularly for young people. Historically, tattoo-related health and safety regulations have focused on rules of hygiene and prevention of infections. Meanwhile, the increasing popularity of tattooing has led to the development of many new colours, allowing tattoos to be more spectacular than ever before. However, little is known about the toxicological risks of the ingredients used. For risk assessment, safe intradermal application of these pigments needs data for toxicity and biokinetics and increased knowledge about the removal of tattoos. Other concerns are the potential for phototoxicity, substance migration, and the possible metabolic conversion of tattoo ink ingredients into toxic substances. Similar considerations apply to cleavage products that are formed during laser-assisted tattoo removal. In this Review, we summarise the issues of concern, putting them into context, and provide perspectives for the assessment of the acute and chronic health effects associated with tattooing.


Subject(s)
Tattooing/adverse effects , Carcinogenesis , Coloring Agents/adverse effects , Dermatitis, Allergic Contact/etiology , Equipment Contamination , Government Regulation , Humans , Infections/etiology , Ink , Laser Therapy , Tattooing/legislation & jurisprudence
2.
N Z Med J ; 128(1410): 71-2, 2015 Mar 13.
Article in English | MEDLINE | ID: mdl-25829042
3.
Pediatr Dermatol ; 31(4): 532-4, 2014.
Article in English | MEDLINE | ID: mdl-23072342

ABSTRACT

A 7-year-old boy developed severe toxic epidermal necrolysis (TEN) secondary to carbamazepine and was transferred to our center after further deterioration despite receiving one dose of intravenous immunoglobulin. After administration of one dose of infliximab, there was a clear halting of progression of blistering and an apparent dramatic improvement. We consider it likely that the administration of infliximab led to the improvement in this child and that anti-tumor necrosis factor-alpha therapy may be a logical treatment for TEN, given the possible underlying pathologic process. Well-conducted studies on the safety and efficacy of any such treatment are urgently required.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Child , Humans , Infliximab , Male
SELECTION OF CITATIONS
SEARCH DETAIL